In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
|Articles|April 3, 2014
Exploring Alternate Payment Models in Oncology
Author(s)Jessica Turgon, MBA
At the ACCC annual meeting, Jessica Turgon, MBA, from ECG Management Consultants discusses how and why providers and payers are beginning to work together to explore alternate payment models in oncology.
Advertisement
At the Association for Community Cancer Centers 40th Annual National Meeting, Jessica Turgon, MBA, from ECG Management Consultants discusses how and why providers and payers are beginning to work together to explore alternate payment models in oncology.
Advertisement
Related to this article
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC
5